NCT07216079View on ClinicalTrials.gov

Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Immune Thrombocytopenia
Interventions
DRUG

rilzabrutinib

Pharmaceutical form:Tablet-Route of administration:Oral

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT07216079 - Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Biotech Hunter | Biotech Hunter